Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET
Company Participants
Marcy Graham - Senior Vice President of Investor Relations and Corporate Communications
Neil Desai - Founder and Executive Chairman
Scott Giacobello - Interim Chief Executive Officer, President, and Chief Financial Officer
Loretta Itri - Chief Medical Officer
Conference Call Participants
Roger Song - Jefferies LLC
Joseph Catanzaro - Piper Sandler
Boris Peaker - Cowen and Company
Ahu Demir - Ladenburg Thalmann & Company
Operator
Good day and welcome to the Aadi Bioscience First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. Instructions will be given at that. As a reminder, this call may be recorded.
Now I'll turn the call over to Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications at Aadi Bioscience. Ms. Graham, please go ahead.
Marcy Graham
Thank you. Good morning and welcome to the Aadi Bioscience conference call to provide an operational update and review results for the first quarter 2023. Joining me on the call today is Scott Giacobello, our CFO and Interim President and CEO who will provide an overview of financial and operational activity during the period, including an update on our continued commercial progress, followed by our Chief Medical Officer, Dr. Loretta Itri, who will provide an update on our PRECISION 1 study and clinical developments and plans for 2023. We will open the line for questions at the end of the call following closing comments.
A quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly filing with the Securities and Exchange Commission which can be found at www.sec.gov or on our website at www.aadibio.com.
In addition, any forward-looking statements made on this call represent our views only as of today, May 10, 2023 and should not be relied upon as representing our view as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that, I will turn the call over to Scott for his opening statements. Scott?
Scott Giacobello
Thank you, Marcy and hello everyone. Thank you for joining us this morning to review our financial and operational results for the first quarter 2023. We're off to a strong start this year as our performance continued to drive results and the first quarter closed out well. Our focus on successful commercial execution of FYARRO for the treatment of advanced malignant PEComa resulted in sales of $5.9 million during the quarter, a 12% sequential increase over the previous quarter.